title: Clinical and histological results in the treatment of atrophic and hypertrophic scars using a combined method of radiofrequency, ultrasound, and transepidermal drug delivery.
abstract: Scars are problematic for thousands of patients. Scarring is a natural part of the healing process after an injury. However, the appearance of a scar and its treatment depend on multiple factors and on the experience of the therapist and the options available. Despite a plethora of rapidly evolving treatment options and technical advances, the management of atrophic and hypertrophic scars remains difficult. Innovative technologies provide an attractive alternative to conventional methods in the treatment of scars. The purpose of this trial was to determine the clinical and histological results of a method of treatment that combines radiofrequency, ultrasound, and transepidermal drug delivery. This was a prospective study conducted on 14 patients with scars of different sizes, types, and characteristics. All patients underwent six treatment sessions with the Legato device. Atrophic scars were treated with retinoic acid and hypertrophic scars with triamcinolone. Photographs and biopsies were taken before treatment and at 6 months after the last treatment session. The scars improved significantly (P < 0.0001). The mean attenuation in the severity of scars was 67% (range: 50-75%), where 100% indicates complete disappearance of the scar. Clinical and histological images of scar tissue in six patients in whom attenuation in the range of 55-75% was achieved are shown. Biopsies show regenerative changes in the scar tissue, in both the epidermis and dermis. The method makes it possible to treat extensive, heterogeneous scars on different sites with good results that are similar and predictable.
authors.affiliation: Instituto Médico Vilafortuny, Cambrils, Tarragona, Spain.
authors.forename: Mario A
authors.initials: MA
authors.lastname: Trelles
authors.affiliation: Clinical Research Unit, IMC-Investiláser, Sabadell, Barcelona, Spain.
authors.forename: Pedro A
authors.initials: PA
authors.lastname: Martínez-Carpio
mesh_terms: D000328:Adult; D000368:Aged; D001284:Atrophy / Q000473:pathology; D001707:Biopsy, Needle; D002921:Cicatrix / Q000473:pathology / Q000628:therapy; D017439:Cicatrix, Hypertrophic / Q000473:pathology* / Q000628:therapy*; D015331:Cohort Studies; D003131:Combined Modality Therapy; D016503:Drug Delivery Systems; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D053685:Laser Therapy / Q000379:methods*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D018570:Risk Assessment; D016896:Treatment Outcome; D014212:Tretinoin / Q000008:administration & dosage*; D014221:Triamcinolone / Q000008:administration & dosage*; D014464:Ultrasonic Therapy / Q000379:methods*; D055815:Young Adult
chemical_list: D014221:Triamcinolone; D014212:Tretinoin